Canaccord Genuity Raises PT and Estimates on Edwards Lifesciences (EW); Preview of Cohort A Panel
Tweet Send to a FriendGet Alerts EW Hot Sheet
Price: $65.53 -0.29%
Rating Summary:
11 Buy, 14 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
11 Buy, 14 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade EW Now!
Canaccord Genuity maintains a 'Buy' on Edwards Lifesciences (NYSE: EW) price target of $103.00 (from $93.00).
Analyst, Jason R. Mills, said, "We expect FDA panel briefing documents for Cohort A to be posted this Monday, ahead of the Circulatory Devices panel Wednesday. We think two-year Cohort A results convincingly demonstrated that TAVI is non-inferior to SAVR in high-risk patients with severe symptomatic aortic stenosis. While we envision a typical “roller coaster” meeting, as panelists contemplate safety data and assess new data that emerged in two-year results, we would be buyers of EW heading into the Panel as we expect a favorable vote, which we do not think is fully contemplated in the stock."
For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.
Shares of Edwards Lifesciences closed at $86.34 yesterday, with a 52 week range of $61.59-$91.50.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Jason R. Mills, said, "We expect FDA panel briefing documents for Cohort A to be posted this Monday, ahead of the Circulatory Devices panel Wednesday. We think two-year Cohort A results convincingly demonstrated that TAVI is non-inferior to SAVR in high-risk patients with severe symptomatic aortic stenosis. While we envision a typical “roller coaster” meeting, as panelists contemplate safety data and assess new data that emerged in two-year results, we would be buyers of EW heading into the Panel as we expect a favorable vote, which we do not think is fully contemplated in the stock."
For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.
Shares of Edwards Lifesciences closed at $86.34 yesterday, with a 52 week range of $61.59-$91.50.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Jefferies Bumps Zumiez (ZUMZ) Numbers Up, But Remains on Sidelines
- Needham & Company Lifts Numbers on Marvell (MRVL) on Solid Results
- Hewlett-Packard (HPQ) Q2 Performance Wins Praise on Wall Street; Jefferies Raises to Hold
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
